US Bancorp DE Cuts Position in McKesson Corporation $MCK

US Bancorp DE cut its stake in McKesson Corporation (NYSE:MCK) by 1.2% during the fourth quarter, HoldingsChannel reports. The fund owned 80,575 shares of the company’s stock after selling 1,002 shares during the quarter. US Bancorp DE’s holdings in McKesson were worth $66,096,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in MCK. GGM Financials LLC purchased a new position in shares of McKesson in the 3rd quarter valued at $25,000. State of Wyoming purchased a new position in shares of McKesson in the 2nd quarter valued at $29,000. Hopwood Financial Services Inc. purchased a new position in shares of McKesson in the 3rd quarter valued at $31,000. Vermillion & White Wealth Management Group LLC purchased a new position in shares of McKesson in the 3rd quarter valued at $33,000. Finally, Board of the Pension Protection Fund purchased a new position in McKesson during the 4th quarter worth $33,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: William Blair initiated coverage with an Outperform rating, calling McKesson’s business a “durable competitive moat” and highlighting specialty-led growth upside — a catalyst for improved investor sentiment and support for McKesson’s premium valuation. William Blair Starts McKesson at Outperform
• Positive Sentiment: McKesson Canada won a national distribution agreement with naturemary, expanding retail reach into thousands of pharmacies — a small but tangible example of continued distribution wins that support recurring revenue. naturemary Secures National Distribution with McKesson Canada
• Neutral Sentiment: Analysts are re‑examining McKesson’s valuation around biosimilars and co‑manufacturing optionality; fair‑value estimates changed only marginally, suggesting upside remains tied to execution on specialty and biosimilar initiatives. Watch pipeline and margin signals. Narrative On McKesson Shifting Around Biosimilars And Valuation Premium
• Neutral Sentiment: McKesson sold its stake in Medical‑Surgical Solutions — a portfolio reshaping move that could free capital or simplify operations, but is unlikely to materially change near‑term earnings. McKesson sells stake in Medical-Surgical Solutions
• Negative Sentiment: Pre‑earnings coverage (Yahoo/Zacks) flags McKesson lacks the “right combination” of factors to produce an earnings beat in the upcoming report, increasing downside risk into the print and making the stock vulnerable to disappointment. McKesson Earnings Expected to Grow: What to Know Ahead of Next Week’s Release Zacks Earnings Preview
• Negative Sentiment: Recent coverage noted McKesson shares fell more sharply than the broader market, reflecting short‑term selling pressure that can amplify downside around cautious headlines or an underwhelming earnings print. McKesson Falls More Steeply Than Broader Market

Insider Transactions at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of McKesson stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $955.00, for a total transaction of $313,240.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total value of $179,550.00. Following the sale, the executive vice president directly owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. This represents a 5.98% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 3,592 shares of company stock worth $3,518,555. 0.08% of the stock is owned by insiders.

McKesson Price Performance

Shares of MCK stock opened at $815.20 on Friday. McKesson Corporation has a 1-year low of $637.00 and a 1-year high of $999.00. The stock’s fifty day moving average price is $894.86 and its 200 day moving average price is $859.16. The company has a market cap of $99.85 billion, a price-to-earnings ratio of 23.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.42.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion during the quarter, compared to analysts’ expectations of $105.98 billion. During the same quarter in the previous year, the firm posted $8.03 EPS. The firm’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities research analysts anticipate that McKesson Corporation will post 39.02 earnings per share for the current year.

McKesson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s payout ratio is currently 9.43%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MCK. Wells Fargo & Company boosted their target price on McKesson from $914.00 to $925.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 5th. Bank of America dropped their target price on McKesson from $1,040.00 to $1,000.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Raymond James Financial set a $970.00 target price on McKesson in a research note on Thursday, March 5th. Robert W. Baird set a $968.00 target price on McKesson in a research note on Wednesday, January 14th. Finally, JPMorgan Chase & Co. boosted their target price on McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $972.27.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.